Fresenius Medical Care runs dialysis clinics and sells the dialysis machines, filters and consumables those clinics use, making it one of the largest kidney care providers in the world. Its structural edge is scale: the installed base of treatment centres and a recurring stream of consumables give it density that smaller competitors cannot easily match, and dialysis demand is inelastic because patients need treatment several times a week. Revenue growth is only 1.4%, so the case rests on margin and cash conversion rather than top-line expansion; operating margin of 10.8% and a 26.4% gross margin are the numbers to test against peers. At 11.4 times trailing earnings and 8.6 times forward, the stock screens cheap relative to its own history and to the broader healthcare services group, but a 8.5% return on equity and a score of 53 out of 100 say the market has reasons for the discount. The deeper look should focus on whether margin can hold as reimbursement pressure and the mix shift toward home and peritoneal dialysis play out.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 14 Oct 2026, 00:00 CEST | Fair value | $33.07 | $39.71 | $21.21 |
| 10 Oct 2026, 00:00 CEST | ACCE price target | $24.00 | first publication | $20.88 |
| 7 Oct 2026, 00:00 CEST | Fair value | $39.71 | $39.30 | $20.22 |
| 4 Oct 2026, 00:00 CEST | Fair value | $39.30 | $40.23 | $19.82 |
| 30 Sept 2026, 00:00 CEST | Fair value | $40.23 | $40.81 | $20.17 |
| 22 Sept 2026, 00:00 CEST | Fair value | $40.81 | $40.18 | $19.37 |
| 19 Sept 2026, 00:00 CEST | Fair value | $40.18 | $41.90 | $19.22 |
| 16 Sept 2026, 00:00 CEST | Fair value | $41.90 | $41.43 | $19.79 |
| 14 Sept 2026, 00:00 CEST | Fair value | $41.43 | $38.14 | $19.28 |
| 8 Sept 2026, 00:00 CEST | Fair value | $38.14 | $38.58 | $19.50 |
Answered from Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| FMS Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) | $22.68 | $33 | 31% below | 11.7x | 8.5% | 56 | 55 |
| FME.DE Fresenius Medical Care | €39.18 | €58 | 32% below | 12.2x | 8.5% | 51 | 55 |
| EHC Encompass Health Corporation Common Stock | $126.01 | $96 | 31% above | 20.8x | 25.0% | 72 | 69 |
| DVA DaVita Inc. Common Stock | $186.10 | $263 | 29% below | 15.7x | 88.5% | 64 | 76 |
| APOLLOHOSP.NS Apollo Hospitals Enterprise Limited | ₹7604.50 | - | - | 53.2x | - | 59 | 50 |
| UHS Universal Health Services Inc. Common Stock | $188.13 | $309 | 39% below | 7.7x | 20.9% | 73 | 71 |
| ENSG The Ensign Group Inc. Common Stock | $178.35 | $126 | 41% above | 27.5x | 17.0% | 50 | 56 |
Where FMS ranks against its sector peers on each metric.